Industry: Cancer treatment
Annate BiTherapeutics is developing a novel antibody capable of binding to cancer cells and killing them.
The particle, TLF (trypanosome lytic factor), is innately present in the human immune system, though at very low levels. Targeting multiple myeloma, a metastatic blood cancer, Annate’s technology can elevate levels of TLF in malignant cells to the point of cell death.
The average yearly cost for treating multiple myeloma can exceed $100,000. Annate’s treatment has the potential to reduce cost drastically less and while improving effectiveness.
Company website: Annate BiTherapeutics